A5018477584- Cancer Immunotherapy and Biomarkers
- Sarcoma Diagnosis and Treatment
- Cutaneous Melanoma Detection and Management
- Dermatological and Skeletal Disorders
- Vascular Tumors and Angiosarcomas
- Cancer Cells and Metastasis
- Cutaneous lymphoproliferative disorders research
- Cancer and Skin Lesions
- Immune cells in cancer
- Chronic Lymphocytic Leukemia Research
- Dermatologic Treatments and Research
- Cardiac tumors and thrombi
- Colorectal Cancer Treatments and Studies
- Protein Tyrosine Phosphatases
- Peptidase Inhibition and Analysis
- Inflammatory Biomarkers in Disease Prognosis
- Skin Diseases and Diabetes
- PI3K/AKT/mTOR signaling in cancer
- Immunotherapy and Immune Responses
- Breast Lesions and Carcinomas
- Melanoma and MAPK Pathways
The Maria Sklodowska-Curie National Research Institute of Oncology
2019-2024
Narodowy Instytut Leków
2022
National Institute of Oncology
2020
Centrum Onkologii
2019
Sarcoma Oncology Center
2018
Background Obesity is a risk factor for malignancy; however, its prognostic role in patients with metastatic melanoma controversial. We aim to investigate the of body mass index (BMI) receiving mitogen-activated pathway kinase inhibitors (MAPKi), immune checkpoint (ICIs) alone or their sequence. Methods Data on ≥1 line systemic treatment were retrieved from prospectively collected databases. Progression-free survival (PFS) and overall (OS) analyzed by means multivariable stratified Cox...
Neutrophil-to-lymphocyte ratio (NLR) has been shown to be prognostic in several solid malignancies. There are limited data regarding its value during novel therapies patients with melanoma. The aim of the study was assess practical utility this BRAF-mutant melanoma treated a combination BRAF and MEK inhibitors (BRAFi/MEKi). We included 215 inoperable or metastatic who underwent BRAFi/MEKi treatment between October 2015 June 2017. Baseline NLR other complete blood count-derived inflammatory...
Background: Recent years have brought the dynamic development of a new method cancer treatment: immunotherapy. Monoclonal antibodies blocking programmed death receptor 1 (PD-1) are now widely used in treatment several malignancies: melanoma, lung, head and neck cancer, among others. The therapeutic benefit immunotherapy soft tissue sarcoma (STS) has not yet been proven. exception is results obtained rare STS subtype alveolar part (ASPS). Case report: We describe case man with diagnosis...
Introduction Epithelioid hemangioendothelioma (EHE) is an ultra-rare sarcoma, marked by distinctive molecular and pathological features with a variable clinical behavior. Its natural history still partially understood, reliable prognostic predictive factors are lacking many questions open on the optimal management. In context of EURACAN, prospective registry specifically dedicated to EHE was developed launched aim providing, through high-quality data collection, better understanding this...
W Polsce wzrasta liczba osob, u ktorych rozpoznano czerniaka skory. Dzieki rozpowszechnianiu wiedzy na temat tego nowotworu coraz cześciej pacjenci zaniepokojeni zmianami skornymi zglaszają sie do lekarza wczesnym etapie rozwoju choroby. Szybka interwencja chirurgiczna daje im szanse calkowite wyleczenie. Niezbedna jest wlaściwa ocena stopnia zaawansowania nowotworu. przypadku wystąpienia wznowy lub progresji choroby istnieje obecnie mozliwośc zastosowania skutecznych terapii. Dlatego tez...
Dzięki pojawieniu się nowych terapii, takich jak inhibitory punktów kontrolnych układu immunologicznego czy BRAF i MEK, w ostatniej dekadzie wyniki leczenia chorych z rozpoznaniem czerniaka uległy znacznej poprawie. W poniższej pracy prezentowany jest przypadek mężczyzny skóry grzbietu, u którego doszło do progresji choroby nowotworowej mimo stosowania uzupełniającego niwolumabem. Chorego następnie zakwalifikowano immunoterapii skojarzonej (niwolumab ipilimumab), która zapewnia największą...
e23529 Background: The oncological staging system should provide meaningful information regarding the patients’ prognosis. For soft tissue sarcomas, available systems include AJCC version 8, 7, and nomogram-based approaches such as SARCULATOR (which additionally includes age subtype). This work compares these using a group of extremity/trunk wall cases liposarcoma (LPS). Methods: We have included all (N = 147) consecutive, newly diagnosed LPS patients treated in our institution between 2010...